Altavant Sciences is a clinical stage biopharmaceutical company formed to advance promising therapies in areas of high unmet medical need with an initial therapeutic focus in pulmonary arterial hypertension.
Altavant’s lead candidate is rodatristat ethyl*, a tryptophan hydroxylase (TPH) inhibitor. TPH inhibitors reduce the body’s peripheral production of serotonin, lowering circulating serotonin levels in diseases characterized by excessive production of the neurotransmitter, including pulmonary arterial hypertension (PAH), certain types of cancer, GI disorders, fibrosis and inflammation. Rodatristat ethyl is currently preparing for Phase 2 clinical development for pulmonary arterial hypertension with a number of additional indications being explored.
The Altavant team is passionate about building a culture that celebrates new ideas and persistence, with a deep commitment to pursue scientific innovation and novel approaches to drug development. We believe that in doing so, we can most effectively impact patients’ lives.
*name applied for; application pending
Our initial program, TPH inhibitors, is based on our understanding of the role of serotonin in impacting various disease states. Serotonin is produced in the body from dietary tryptophan. Although best known for its role as a neurotransmitter in the CNS, it has numerous roles throughout the body in both physiologic and pathologic processes. Elevated levels of serotonin or increased serotonin activity in the periphery has been implicated in the pathophysiology of a variety of diseases such as pulmonary arterial hypertension (PAH), certain types of cancer, GI disorders, fibrosis, and inflammation. Our research team is actively exploring many of these hypotheses and we hope to advance programs targeting one or more of these indications in the near future.
Pulmonary Arterial Hypertension
Our lead indication is pulmonary arterial hypertension (PAH) where we believe serotonin elevation plays a critical role. PAH is a rare disease that affects the arteries in the lungs and the right side of the heart. PAH results in increased pressure within the lungs’ arteries, causing the heart muscle to weaken and eventually fail. PAH is a progressive, life-threatening illness without a cure. While various treatment options exist, patients are in need of additional treatment options that offer hope for disease modification and symptom improvement via novel approaches.